Century Therapeutics reports CNTY-813 nonclinical data at EASD; IND filing on track for Q4 2026

Century Therapeutics, Inc.

CNTY-813 maintained glycemic control in diabetic mice over an 11-month study until graft removal; all streptozotocin-induced diabetic mice dosed with CNTY-813 achieved normoglycemia.
Five clinical-scale GMP batches produced consistent product via a 29-day process that exceeded purity criteria at every stage.
Clinical-scale islets stored 96 hours cold normalized blood glucose in mice within 30 days and held normoglycemia through three months.
Rat liver portal vein delivery yielded engraftment at one month, with islets staining positive for chromogranin A and insulin.
CEO Brent Pfeiffenberger said the CNTY-813 IND submission remains on track for Q4 2026, with initial clinical data anticipated in 2H 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.